Document text
Principal Investigator: MARC NICKLAUS
Organization: DIVISION OF BASIC SCIENCES - NCI
Fiscal Year: 2023
Award: $138,509
Funding agency: National Cancer Institute
In collaboration with several Principal Investigators at the CCR/NCI, in silico screening of large small-molecule databases are being conducted for a number of molecular targets relevant for cancer. We are using the CADD Group's resources, including our screening databases to generate lists of compounds to be purchased from commercial suppliers, with the goal of obtaining novel lead compounds in in vitro and/or cell-based assays. We have been working with Julieta Comin, Instituto Nacional de Tecnologia Industrial, Argentina; herpes thymidine kinase, in collaboration with Victor E. Marquez, formerly Laboratory of Medicinal Chemistry, CCR, NCI; bis-imidazoacridone DNA intercalators, in collaboration with Sergey Tarasov, CSB, CCR, NCI; small-molecule mimetics of a surface patch of thrombospondin-1 (TSP1) interacting with CD47 as well as for the interacting SIRP-alpha protein, in collaboration with David D. Roberts, Laboratory of Pathology, CCR, NCI; the interaction of the transcription factor HIF-1 alpha with cofactor p300, in collaboration with William Douglas Figg Sr., GMB, CCR, NCI; the development of targeted therapy for CBF leukemias by targeting the CBF-beta and Runx1 interaction, in collaboration with Paul Liu, NHGRI, NIH; in silico screening and modeling support for screening for SUMOylation inhibitors, in collaboration with John S. Schneekloth, Jr., CBL, CCR, NCI; modeling support for screening for lysine acetyltransferase inhibitors, in collaboration with Jordan Meier, CBL, CCR, NCI; modeling and in silico screening for inhibitors of C-Terminal Binding protein, in collaboration with Kevin Gardner, Columbia University Medical Center, New York, NY. A collaboration in this area is with Jeff Gildersleeve, CBL, CCR, NCI, on the Immunological Evolution of Therapeutic Antibodies to Ganglioside GD2. A collaboration is with Jay Schneekloth about HRAS. Recent in silico screening collaborations are with Euna Yoo on USP18, Martin Schnermann on PBD dimers, Andre Nussenzweig on Werner helicase, Stan Lipkowitz on Cbl-b, Doug Figg/Dong Seok Kim (AevisBio) on thalidomide analogs, Kevin Gardner on CtBP, and Javed Khan & Bob Hawley on KDM3B. A very important part of our in silico screening collaboration is with Nadya Tarasova, CIL, CCR, NCI, in the context of our SAVI project, by applying the SAVI Database to find active molecules against cancer, SARS-Cov-2 targets, and, to some extent, HIV-1, targets. A recent success story involves our work on STAT3 N-terminal domain (ND), is a promising target since it has been shown that a STAT3 ND lipopeptide inhibitor induces cell death through activation of proapoptotic genes in tumor cells but not normal epithelial cells. Such inhibitors also showed immune stimulatory properties and caused significant reduction in bacterial count in mice chronically infected with Mycobacterium tuberculosis by activating host immune responses. The STAT3 ND structure was tested experimentally to find a druggable pocket. Out of four analyzed, one pocket next to its dimerization interface was found by Dr. Tarasova's group to yield small molecule leads in the screening that are more potent than lipopeptide STAT3 ND inhibitors. The compounds suppress STAT3 signaling and are selectively toxic to tumor cells. An International Patent Application (No. PCT/US2021/058936) for these compounds was filed November 11, 2021 with the title SMALL MOLECULE INHIBITORS OF STAT3 N-TERMINAL DOMAIN AND METHODS OF USE. The time from initial in silico screening to patent application was just 15 months, which included all the slowdowns caused by the COVID-19 pandemic such as shutdown of wet labs for months and delays in synthesis and shipping of compounds from Enamine. Additional recent enhancement to the screening workflow involves the use of MolSoft's program RIDE that allows to efficiently screen the entire database to select the most promising leads, plus MolSoft's rapid, GPU-based docking tool RIDGE.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Academic Medical Centers><Acetyltransferase><Apoptotic><Area><Argentina><Assay><Bacterial Counts><Basal Transcription Factor><Basal transcription factor genes><Basic Mechanisms of SUMOylation><Bioassay><Biologic Assays><Biological Assay><C-terminal binding protein><CBF><CBL><CBL gene><CBL2><CCR><CD47><CD47 Antigen><CD47 Glycoprotein><CD47 gene><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 virus><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 virus><Cancers><Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence><Cell Body><Cell Communication and Signaling><Cell Death Induction><Cell Signaling><Cells><Chronic><Clinical><CoV-2><CoV2><Collaborations><Computer software><Core-Binding Factor><CtBP protein><DNA><DNA Helicases><DNA Intercalating Agent><DNA Unwinding Proteins><DNA unwinding enzyme><Data Bases><Databases><Deoxypyrimidine Kinase><Deoxyribonucleic Acid><Deoxythymidine Kinase><Development><Dimerization><Docking><E1A Binding Protein p300><EP300><EP300 gene><Epithelial Cells><Evolution><Ganglioside GD2><General Transcription Factor Gene><General Transcription Factors><Genes><Goals><H-ras><H-ras Gene><H-ras Oncogene><HIF 1 alpha><HIF-1alpha><HIF1-Alpha><HIF1A><HIF1A gene><HIF1α><HIV-1><HIV-I><HIV1><HRAS><HRAS gene><HRAS1><Harvey Rat Sarcoma Viral Oncogene Homolog><Human Immunodeficiency Virus Type 1><Human immunodeficiency virus 1><Immune><Immune response><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><In Vitro><Industrialization><Integrin-Associated Protein><Intercalating Agents><Intercalating Ligands><Intercalative Compounds><Intercalators><International><Intracellular Communication and Signaling><Jordan><KAT3B><L-Lysine><Laboratories><Legal patent><Lysine><M tb><M tuberculosis><M. tb><M. tuberculosis><MER6><MFR gene><MFR protein><MOP1><MYD-1><Macrophage Fusion Receptor><Malignant Neoplasms><Malignant Tumor><Medicinal Chemistry><Methods><Mice><Mice Mammals><Modeling><Molecular Target><Murine><Mus><Mycobacterium tuberculosis><N-terminal><NH2-terminal><NHGRI><NIH><National Center for Human Genome Research><National Human Genome Research Institute><National Institutes of Health><New York><P84><PTPNS1><PTPNS1 gene><Patents><Pathology><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Principal Investigator><Property><Protein Dimerization><Protein-Tyrosine Phosphatase, Nonreceptor Type, Substrate 1><Proteins><RAS genes><RASH1><Research Resources><Resources><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SHP Substrate 1><SHPS1><SIRP-Alpha-1><SIRPA><STAT3><STAT3 gene><SUMOylation><Screening for cancer><Sedalis><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Shipping><Signal Regulatory Protein, Alpha Type, 1><Signal Transduction><Signal Transduction Systems><Signaling><Software><Structure><Sumoylation Pathway><Surface><Surface Antigen Identified by Monoclonal Antibody 1D8><TSP-1><TSP1><Testing><Thalidomide><Therapeutic antibodies><Thrombospondin 1><Thymidine Kinase><Time><Transcription Factor Proto-Oncogene><Transcription factor genes><Tumor Cell><Tyrosine Phosphatase SHP Substrate 1><United States National Institutes of Health><University Medical Centers><Work><Wuhan coronavirus><analog><biological signal transduction><cofactor><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><data base><design><designing><developmental><dimer><early cancer detection><hCoV19><helicase><histone acetyltransferase p300><host response><immune system response><immunoresponse><in silico><inhibitor><interest><leukemia><malignancy><mimetics><mtb><nCoV2><neoplasm/cancer><neoplastic cell><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel lead compound><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><p300><programs><screening><screening cancer patients><screenings><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><small molecule><small molecule inhibitor><success><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tool><transcription factor><v-Ha-RAS Harvey Rat Sarcoma Viral Oncogene Homolog>